Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. is a U.S.-based late-stage pharmaceutical company focused on discovering, developing, and seeking to commercialize new medicines for central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline centers on two internally discovered drug candidates, brilaroxazine (RP5063) and RP1208, supported by a proprietary chemistry and chemical genomics platform and a patent portfolio spanning the U.S., Europe, and other countries.

2.08

2.08

— Reviva Pharmaceuticals Holdings, Inc.
%
Lead drug candidate development60% Development of brilaroxazine (RP5063) and related clinical-stage programs.
Second pipeline asset20% Development of RP1208 and related preclinical or clinical work.
Discovery platform10% Chemical genomics and proprietary chemistry used to identify new medicines.
Intellectual property10% Patents and patent applications protecting compounds and methods of use.

Reviva does not sell to a broad commercial customer base today; its primary counterparties are regulators, clinical...

  • Regulators and approval authoritiesprimary

    FDA and other agencies review trial data and determine whether candidates can advance or be approved.

  • Clinical trial sites and investigatorsprimary

    Hospitals, clinics, and investigators enroll patients and generate the safety/efficacy data needed for development.

  • Pharmaceutical partnerssecondary

    Potential collaborators or licensees may support development, manufacturing, or commercialization.

  • Future prescribers and patientsemerging

    Psychiatrists and other specialists would use approved products if the pipeline reaches market.

Reviva is headquartered in the United States and operates as a U.S.-listed development-stage pharmaceutical company...

  • •Headquartered and listed in the United States
  • •Clinical and regulatory work is centered on U.S. development pathways
  • •Patent coverage extends across Europe and over 20 foreign countries
  • •Future commercialization would depend on approvals in multiple jurisdictions
  • •Global IP coverage helps protect pipeline value outside the U.S.

Reviva’s strategy is to advance its two internally discovered drug candidates through late-stage clinical development...

01
Complete late-stage clinical development of brilaroxazineshort-term

Clinical success is the main value driver for a development-stage pharmaceutical company.

02
Maintain and expand intellectual property protectionmedium-term

Patent exclusivity is essential to defend future commercial value and partnering leverage.

03
Raise capital to fund development and operationsshort-term

Clinical programs require ongoing funding before any product revenue can be generated.

Reviva faces the typical risks of a clinical-stage biotech company: trial failure, regulatory rejection, and the need...

critical

Clinical development failure

Pipeline value depends on positive trial outcomes and successful progression through phases.

Scope
Brilaroxazine and RP1208
Materiality
high
critical

Financing and going-concern risk

The company has no commercial product revenue and relies on external capital to fund operations.

Scope
Equity, debt, ATM issuance, collaborations
Materiality
high
high

Regulatory approval risk

FDA or other authorities may require additional data or reject applications.

Scope
U.S. and foreign jurisdictions
Materiality
high
high

Manufacturing and supply chain dependence

Clinical and future commercial supply depends on third-party manufacturers and raw materials.

Scope
Contract manufacturing and sourcing
Materiality
medium
high

Intellectual property protection

Patent scope and enforceability determine the duration of competitive exclusivity.

Scope
Brilaroxazine, RP1208, related compounds
Materiality
high
Clinical trial expense recognition
Affects R&D expense and quarterly loss volatility
Fair value of warrant liabilities
Can materially affect net income (loss) and volatility
Stock-based compensation
Increases operating expenses without immediate cash outflow
Going-concern assessment
Influences disclosure and investor assessment of financing risk

MEDICINOVA INC

MNOV · Pharmaceutical Preparations

RELMADA THERAPEUTICS, INC.

RLMD · Pharmaceutical Preparations

Serina Therapeutics, Inc.

SER · Pharmaceutical Preparations

Innoviva, Inc.

INVA · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

Rezolute, Inc.

RZLT · Pharmaceutical Preparations

: 29/04/2026